Millie
your market intelligence analyst
Search Results
81 results
Your search is now limited to «Non-Hodgkin Lymphoma» expert search.
Cancer Network 11/13/2019
Overcoming resistance and determining better treatment plans that address the underlying disease biology of mantle cell lymphoma.
More from Cancer Network:
Further study with a larger sample size is needed to verify these biomarkers in predicting lymphoma CNS involvement.
More from International Journal of COPD:
BioNewsFeeds 11/08/2019 14:00
The trial is expected to enroll 900 patients with several lymphoma types, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma.
More from BioNewsFeeds:
PR Newswire 11/08/2019 02:32
BioInvent CEO Martin Welschof said: "These pre-clinical data indicate a broad and clinically important role of FcγRIIb in mantle cell lymphoma, and highlight the potential of BI-1206 to help overcome resistance in this indication.
More from PR Newswire:
Onclive 11/06/2019 10:31
With a variety of available agents in follicular lymphoma, determining which treatments to choose and how best to sequence them can be challenging.
More from Onclive:
Business Wire 11/06/2019 09:15
COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)_after at least two prior therapies and in relapsed or refractory follicular lymphoma (FL) after at least two prior system therapies.
More from Business Wire:
Results from a cohort of patients with follicular lymphoma (FL) will be reported separately.
More from American Society of Clinical Oncolgy (ASCO):
PubMed News (NIH) 11/01/2019
Contributors : Haiwen Ni ; Isere Kuiatse ; Fazal Shirazi ; Hua Wang ; Richard J Jones ; Zhiqiang Wang ; R E Davis ; Robert Z Orlowski Series Type : Expression profiling by array Organism : Homo sapiens. The L265P mutation in MYD88 is very frequent in tumor cells of Waldenström’s macroglobulinemia (WM), and activates NF-kappaB through IRAK1 and IRAK4.
More from PubMed News (NIH):
Targeted Oncology 10/30/2019 18:13
Umbralisib (TGR-1202) monotherapy demonstrated positive responses in patients with previously treated follicular lymphoma, meeting the primary end point for the follicular lymphoma cohort of the phase IIb UNITY-NHL trial, TG Therapeutics announced in a press release.
More from Targeted Oncology:
ClinicalTrials.gov 10/23/2019 08:56
Conditions : Multiple Myeloma; Non Hodgkin Lymphoma Interventions : Drug: NKTR-255; Drug: Daratumumab Sponsor : Nektar Therapeutics Recruiting.
More from ClinicalTrials.gov:
The International Response Criteria for non-Hodgkin's Lymphoma was used to assess response (12.
More from Clinical Cancer Research - Recent Issues (abstracts):
If approved, COPIKTRA will add to the company's already approved product list, with its first FDA approved product now available for the treatment of patients with certain types of indolent non-Hodgkin's lymphoma (iNHL.
More from Middle East North Africa Financial Network (MENAFN):
When and fail, some adult patients with B-cell or children with acute lymphoblastic have a new treatment option called . Yescarta is the CAR T-cell therapy that’s FDA-approved to treat patients with B-cell non-Hodgkin’s lymphoma; it shrinks the tumors in 70-80% of patients. But with this new therapy come side effects that are different from those of other cancer treatments. To better understand these side effects in adult lymphoma patients, we talked with. How does CAR T-cell therapy work? Like other types of , CAR T-cell therapy uses the patient’s own immune system to treat cancer. T cells – one type of the immune system’s fighter cells – are extracted from the patient, modified in a lab and then transfused back into the patient. During the.
More from Cancerwise | Cancer blog from MD Anderson Cancer Center:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications